Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Glancy Binkow & Goldberg LLP Announces Investigation on Behalf of Shareholders of Chemed Corporation



  Glancy Binkow & Goldberg LLP Announces Investigation on Behalf of
  Shareholders of Chemed Corporation

Business Wire

LOS ANGELES -- September 18, 2013

Glancy Binkow & Goldberg LLP announces that it is investigating potential
claims on behalf of shareholders of Chemed Corporation (“Chemed” or the
“Company”) (NYSE:CHE) concerning possible breaches of fiduciary duties by the
Company or its fiduciaries. Chemed, through its subsidiaries, operates in the
healthcare and repair and maintenance fields in the United States. The
Company’s Vitas segment offers hospice and palliative patient-care services
through a network of physicians, registered nurses, home health aides, social
workers, clergy and volunteers.

Please contact us at (212) 682-5340, toll-free at (888) 773-9224, or at
shareholders@glancylaw.com to discuss this matter. If you inquire by email,
please include your mailing address, telephone number and number of shares
purchased.

The investigation is related to allegations that Chemed billed Medicare for
unnecessary and fraudulent treatments – including billing for hospice care for
patients who were not terminally ill – and whether the Company’s board of
directors breached their fiduciary duties or allowed Chemed to engage in
potential violations of the federal False Claims Act. In May 2013, the United
States Department of Justice filed a lawsuit under the False Claims Act
against Chemed and its affiliates, alleging that the Company systematically
defrauded Medicare.

If you purchased Chemed shares and still hold those shares, if you have
information or would like to learn more about these claims, or if you wish to
discuss these matters or have any questions concerning this announcement or
your rights or interests with respect to these matters, please contact Michael
Goldberg, Esquire, of Glancy Binkow & Goldberg LLP, 1925 Century Park East,
Suite 2100, Los Angeles, California 90067, Toll Free at (888) 773-9224, or
contact Gregory Linkh, Esquire, of Glancy Binkow & Goldberg LLP at 122 E. 42nd
Street, Suite 2920, New York, New York 10168, at (212) 682-5340, by e-mail to
shareholders@glancylaw.com, or visit our website at http://www.glancylaw.com.
If you inquire by email please include your mailing address, telephone number
and number of shares purchased.

This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and ethical rules.

Contact:

Glancy Binkow & Goldberg LLP
Los Angeles, CA
Michael Goldberg, 888-773-9224
or
New York, NY
Gregory Linkh, 212-682-5340 or 888-773-9224
or
shareholders@glancylaw.com
www.glancylaw.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement